Purpose. To evaluate the effect of intravitreal triamcinolone acetonide on visual acuity in branch retinal vein occlusion. Methods. The prospective comparative nonrandomized clinical interventional study included 28 p...Purpose. To evaluate the effect of intravitreal triamcinolone acetonide on visual acuity in branch retinal vein occlusion. Methods. The prospective comparative nonrandomized clinical interventional study included 28 patients (28 eyes) with branch retinal vein occlusion. The study group consisting of 10 consecutive patients received an intravitreal injection of 20- 25mg of triamcinolone acetonide. The control group including 18 patients did not receive an intravitreal injection. The mean follow-up was 8.7± 4.4 months. Results. In the study group, mean visual acuity increased significantly (P=0.02) from 0.27± 0.11 preoperatively to a best postoperative visual acuity of 0.45± 0.27. Visual acuity measurements determined 1 month after the injection were significantly (P=0.027) higher than baseline values. Nine (90% ) eyes gained in visual acuity, with six (60% ) eyes showing an increase in visual acuity of at least two Snellen lines. In the ischaemic subgroup, visual acuity did not change significantly (0.18± 0.18 to 0.13± 0.04; P=0.66), while, in the nonischaemic subgroup, visual acuity increased significantly (P=0.012) from the baseline value to the best postoperative measurement (0.29± 0.09 to 0.53± 0.24). In the control group, baseline visual acuity and best visual acuity during the follow-up did not vary significantly (P=0.27). Comparing the study and control groups with each other, the gain in visual acuity was significantly higher in the study group at 1 month (P=0.016) and 2 months (P=0.012) after baseline. Conclusions. Intravitreal injection of triamcinolone acetonide can increase visual acuity in patients with branch retinal vein occlusion.展开更多
To report side effects after intravitreal high-dose reinjections of triamcino lone acetonide. Clinical interventional case series. Forty-six patients (47 eye s) received at least two intravitreal injections of approxi...To report side effects after intravitreal high-dose reinjections of triamcino lone acetonide. Clinical interventional case series. Forty-six patients (47 eye s) received at least two intravitreal injections of approximately 20 to 25 mg tr iamcinolone acetonide for treatment of diabetic macular edema (n=6 eyes), exudat ive age-related macular degeneration (n=23), and other diseases. Intervals betw een injections were 6.7 ±3.4 months, 8.0 ±4.6 months, and 10.2 months, respect ively, before the second (n=47 eyes), third (n=9), and fourth (n=2) injection. M ean follow-up was 20.7±8.9 months. After no reinjection were complications det ected, other than those known to occur after a single intravitreal injection. Af ter the first, second, and third injection, respectively, intraocular pressure r emained normal in 24 (51%), 25 (53%), and 26(56%)eyes. Intravitreal high-dos age reinjections of triamcinolone acetonide may be tolerated within a mean follo w-up of approximately 21 months.展开更多
Aim: To report on visual outcome of patients receiving an intravitreal injecti on of triamcinolone acetonide for treatment of diffuse diabetic macular oedema. Methods: Prospective, comparative, non-randomised clinical...Aim: To report on visual outcome of patients receiving an intravitreal injecti on of triamcinolone acetonide for treatment of diffuse diabetic macular oedema. Methods: Prospective, comparative, non-randomised clinical interventional study included 136 patients with diffuse diabetic macular oedema. Patients of the stu dy group (97 eyes) received an intravitreal injection of 20-25 mg of triamcinol one acetonide and no other retinal treatment. Patients of the control group (69 eyes) received focal or panretinal laser treatment if indicated. Mean (standard deviation) follow up was 8.4 (SD 6.0) months (range 1.03-25.2 months). Results: Visual acuity (VA) increased significantly (p< 0.001) in the study group with 6 6 (68%) eyes gaining in VA by at least two Snellen lines. In the control group, VA did not change significantly during the first 4 months of follow up, and dec reased significantly (p< 0.001) towards the end of the follow up. Difference in change of best VA was significant (p< 0.001) between both groups. Correspondingl y, the number of patients with VA improvement of two or more Snellen lines and v isual loss of two or more Snellen lines, respectively, was significantly (p< 0.0 01) higher and lower, respectively, in the study group. Conclusions: Intravitrea l triamcinolone acetonide can temporarily increase VA in some patients with diff use diabetic macular oedema.展开更多
文摘Purpose. To evaluate the effect of intravitreal triamcinolone acetonide on visual acuity in branch retinal vein occlusion. Methods. The prospective comparative nonrandomized clinical interventional study included 28 patients (28 eyes) with branch retinal vein occlusion. The study group consisting of 10 consecutive patients received an intravitreal injection of 20- 25mg of triamcinolone acetonide. The control group including 18 patients did not receive an intravitreal injection. The mean follow-up was 8.7± 4.4 months. Results. In the study group, mean visual acuity increased significantly (P=0.02) from 0.27± 0.11 preoperatively to a best postoperative visual acuity of 0.45± 0.27. Visual acuity measurements determined 1 month after the injection were significantly (P=0.027) higher than baseline values. Nine (90% ) eyes gained in visual acuity, with six (60% ) eyes showing an increase in visual acuity of at least two Snellen lines. In the ischaemic subgroup, visual acuity did not change significantly (0.18± 0.18 to 0.13± 0.04; P=0.66), while, in the nonischaemic subgroup, visual acuity increased significantly (P=0.012) from the baseline value to the best postoperative measurement (0.29± 0.09 to 0.53± 0.24). In the control group, baseline visual acuity and best visual acuity during the follow-up did not vary significantly (P=0.27). Comparing the study and control groups with each other, the gain in visual acuity was significantly higher in the study group at 1 month (P=0.016) and 2 months (P=0.012) after baseline. Conclusions. Intravitreal injection of triamcinolone acetonide can increase visual acuity in patients with branch retinal vein occlusion.
文摘To report side effects after intravitreal high-dose reinjections of triamcino lone acetonide. Clinical interventional case series. Forty-six patients (47 eye s) received at least two intravitreal injections of approximately 20 to 25 mg tr iamcinolone acetonide for treatment of diabetic macular edema (n=6 eyes), exudat ive age-related macular degeneration (n=23), and other diseases. Intervals betw een injections were 6.7 ±3.4 months, 8.0 ±4.6 months, and 10.2 months, respect ively, before the second (n=47 eyes), third (n=9), and fourth (n=2) injection. M ean follow-up was 20.7±8.9 months. After no reinjection were complications det ected, other than those known to occur after a single intravitreal injection. Af ter the first, second, and third injection, respectively, intraocular pressure r emained normal in 24 (51%), 25 (53%), and 26(56%)eyes. Intravitreal high-dos age reinjections of triamcinolone acetonide may be tolerated within a mean follo w-up of approximately 21 months.
文摘Aim: To report on visual outcome of patients receiving an intravitreal injecti on of triamcinolone acetonide for treatment of diffuse diabetic macular oedema. Methods: Prospective, comparative, non-randomised clinical interventional study included 136 patients with diffuse diabetic macular oedema. Patients of the stu dy group (97 eyes) received an intravitreal injection of 20-25 mg of triamcinol one acetonide and no other retinal treatment. Patients of the control group (69 eyes) received focal or panretinal laser treatment if indicated. Mean (standard deviation) follow up was 8.4 (SD 6.0) months (range 1.03-25.2 months). Results: Visual acuity (VA) increased significantly (p< 0.001) in the study group with 6 6 (68%) eyes gaining in VA by at least two Snellen lines. In the control group, VA did not change significantly during the first 4 months of follow up, and dec reased significantly (p< 0.001) towards the end of the follow up. Difference in change of best VA was significant (p< 0.001) between both groups. Correspondingl y, the number of patients with VA improvement of two or more Snellen lines and v isual loss of two or more Snellen lines, respectively, was significantly (p< 0.0 01) higher and lower, respectively, in the study group. Conclusions: Intravitrea l triamcinolone acetonide can temporarily increase VA in some patients with diff use diabetic macular oedema.
